Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Int. braz. j. urol ; 44(5): 1014-1022, Sept.-Oct. 2018. tab, graf
Article in English | LILACS | ID: biblio-975626

ABSTRACT

ABSTRACT Objective: To evaluate the effect of intravesical hyaluronic acid (HA) treatment on inflammatory cells and the severity of inflammation in an interstitial cystitis rat model created with hydrogen chloride (HCL) via immunohistochemical studies and myeloperoxidase activity for the first time in the literature. Materials and Methods: A total of 30 adult female white Rattus Norvegicus rats were divided into 3 groups as the HCL group, hyaluronic acid treatment (HCL-HA) group and control group. Chemical cystitis was created by administering HCL(400 microL,10 mM) except control group. A single dose of intravesical HA(0.5 mL,0.8 mg/mL) was administered to the treatment group. The bladder tissues of all subjects were immunohistochemically stained. The cell surface markers were used to evaluate inflammatory cell infiltration. Mast cell activation and IL-6 was evaluated to assess the inflammation and severity of inflammation, respectively. Myeloperoxidase activity was measured as it shows neutrophil density. Statistical significance was accepted as P<0.05. Results: It was observed that there was rich monocyte, T lymphocyte, B lymphocyte, and Natural Killer cells infiltration and high IL-6 levels in the bladder tissue after the intravesical hydrogen chloride instillation, especially in the stroma layer(p<0.005). In the HCL-HA group, severity of inflammation had statistically significantly regressed to the levels of the control group(p<0.005). An increase was observed in the bladder myeloperoxidase activity of the HCL group compared to the other two groups(p<0.05). Conclusions: Single dose intravesical hyluronic acid instillation reduces inflammatory cell infiltration and the severity of bladder inflammation in the rat model of bladder pain syndrome/interstitial cystitis.


Subject(s)
Animals , Female , Rats , Urinary Bladder/drug effects , Cystitis, Interstitial/drug therapy , Hyaluronic Acid/therapeutic use , Urinary Bladder/pathology , Severity of Illness Index , Administration, Intravesical , Cystitis, Interstitial/chemically induced , Cystitis, Interstitial/pathology , Disease Models, Animal , Hydrochloric Acid
2.
Int. braz. j. urol ; 43(1): 95-103, Jan.-Feb. 2017. tab, graf
Article in English | LILACS | ID: biblio-840801

ABSTRACT

ABSTRACT Objectives To investigate the impact of neck circumference (NC) in the treatment of bening prostatic hyperplasia (BPH) patients with metabolic syndrome (MtS). Additionally, we determined dose response to alpha-blockers and cut-off values for NC and waist circumference (WC), in these patients. Materials and Methods Non-randomized, open-labelled, and multi-centre study was conducted between March 2014 and September 2015. The BPH patients were enrolled and were divided into 2 groups: with MtS (Group 1; n=94) and without MtS (Group 2; n=103). Demographic data, anthropometric measurements, blood analyses, uroflowmetric parameters, post voiding residual urine (PVR), prostate volume, quality of life (QoL) index, NC and WC were recorded. Both groups were administered oral alpha-blockers and response to treatment was evaluated. Receiver-operating characteristic (ROC) curves were obtained and significant p was p<0.05 . Results In total, 197 patients were enrolled with mean age of 60.5±8.1 years. Mean NC and WC were higher in MtS patients (p<0.001). Uroflowmetry parameters and QoL indexes were comparable between groups before treatment. International prostate symptom score, uroflowmetry parameters, and QoL significant improved in Group 2 than Group 1, at 1 st and 6 th months of treatment with alpha-blockers. Success rate of treatment was significant higher in Group 2 than Group 1 (p<0.001). Cut-off values were 42.5cm and 113.5cm for NC and WC respectively, for response to alpha-blockers in BPH patients with MtS. Conclusions MtS can be related with BPH and can negatively affect the response to alpha-blocker treatment. NC can be used for predicting response to alpha-blocker treatment in BPH patients with MtS.


Subject(s)
Humans , Male , Aged , Prostatic Hyperplasia/physiopathology , Prostatic Hyperplasia/drug therapy , Adrenergic alpha-Antagonists/therapeutic use , Metabolic Syndrome/complications , Metabolic Syndrome/physiopathology , Waist Circumference/physiology , Neck/anatomy & histology , Quality of Life , Reference Values , Body Mass Index , Predictive Value of Tests , Prospective Studies , Reproducibility of Results , ROC Curve , Analysis of Variance , Treatment Outcome , Prostate-Specific Antigen/blood , Body Size/physiology , Dose-Response Relationship, Drug , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL